Diaceutics' (DXRX) "Buy" Rating Reaffirmed at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Diaceutics (LON:DXRX - Free Report) in a report released on Tuesday morning, MarketBeat reports. The brokerage currently has a GBX 180 ($2.43) price objective on the stock.

Separately, Royal Bank Of Canada reduced their price objective on Diaceutics from GBX 195 ($2.63) to GBX 185 ($2.50) and set an "outperform" rating on the stock in a research report on Thursday, July 10th.

Diaceutics Stock Performance

Shares of LON:DXRX traded up GBX 3 ($0.04) during trading on Tuesday, hitting GBX 133 ($1.80). 1,022,184 shares of the company were exchanged, compared to its average volume of 144,077. The stock has a 50 day moving average of GBX 125.06 and a 200 day moving average of GBX 128.41. The company has a market cap of £112.24 million, a PE ratio of -39.45 and a beta of 0.58. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92. Diaceutics has a 52-week low of GBX 106 ($1.43) and a 52-week high of GBX 151 ($2.04).

Diaceutics (LON:DXRX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported GBX (2.02) (($0.03)) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%. As a group, equities research analysts predict that Diaceutics will post 1.0107919 EPS for the current year.

Insider Activity

In other Diaceutics news, insider Peter Keeling sold 500,000 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of GBX 126 ($1.70), for a total value of £630,000 ($851,006.35). Corporate insiders own 34.30% of the company's stock.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.